Neuros Medical completed $56 million Series D Round funding
Sector:
MedTech
07/09/2025
Aliso Viejo, CA USA
Neuros Medical
completed $56 million Series D Round funding. Investors include
EQT Ventures (lead), USVP, Osage University Partners, Sectoral Asset Management, Aperture Venture Partners.
"I would like to thank our new and existing investors for their support in our mission to relieve pain and restore life for the millions of people suffering from chronic post-amputation pain," said David Veino, President & CEO, Neuros Medical. "This funding round is a strong validation of the unmet medical need in the amputee community and allows us to scale our commercial operations to expand access to this breakthrough technology, while equipping healthcare professionals with a non-opioid solution and support they need to deliver the highest standard of care."
About
There are nearly two million amputees in the U.S., with 300,000 new amputations occurring every year.1 Post-amputation pain includes both phantom limb pain and residual limb pain, and impacts up to 80% of amputees, representing a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.2 Neuros Medical is a privately held company and the maker of the Altius® Direct Electrical Nerve Stimulation System which is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Our mission is to reduce pain and restore life for people suffering with post-amputation pain. We are a passionate team guided by our core values and committed to our patients and the healthcare professionals who care for them.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
